Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic Migraine.

Francesca Schiano di Cola,Marco Bolchini,Salvatore Caratozzolo,Giulia Ceccardi,Matteo Cortinovis,Paolo Liberini,Renata Rao,Alessandro Padovani

Neurology international（2023）

引用 1|浏览5

暂无评分

摘要

Monthly prophylactic treatment with galcanezumab was found to be effective in both CM and HFEM, especially in reducing migraine burden and disability.

查看译文

关键词

CGRP,HIT-6,MIDAS,burden,disability,galcanezumab,migraine

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要